Literature DB >> 17513868

MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties.

Qing Sun1, Christopher R Weber, Anjum Sohail, M Margarida Bernardo, Marta Toth, Huiren Zhao, Jerrold R Turner, Rafael Fridman.   

Abstract

MMP25 (MT6-MMP) is one of the two glycosylphosphatidylinositol-anchored matrix metalloproteinases (MMPs) that have been suggested to play a role in pericellular proteolysis. However, its role in cancer is unknown, and its biochemical properties are not well established. Here we found a marked increase in MT6-MMP expression within in situ dysplasia and invasive cancer in 61 samples of human colon cancer. Expression of MT6-MMP in HCT-116 human colon cancer cells promoted tumori-genesis in nude mice. Histologically, the MT6-MMP-expressing tumors demonstrated an infiltrative leading edge in contrast to a rounded leading edge in vector control tumors. Biochemical and biosynthesis analyses revealed that MT6-MMP displayed on the cell surface exists as a major form of 120 kDa that likely represents enzyme homodimers linked by disulfide bonds. Upon reduction, a single 57-kDa active MT6-MMP was detected. Interestingly, neither membrane-anchored nor phosphatidylinositol-specific phospholipase C-released MT6-MMPs were found to be associated with tissue inhibitor of metalloproteinases (TIMPs) and did not activate pro-gelatinases (pro-MMP-2 and pro-MMP-9) even in the presence of exogenous TIMP-2 or TIMP-1. A catalytic domain of MT6-MMP was inhibited preferentially by TIMP-1 (K(i) = 0.2 nm) over TIMP-2 (K(i) = 2.0 nm), because of a slower association rate. These results show that MT6-MMP may play a role in colon cancer and exhibit unique biochemical and structural properties that may regulate proteolytic function at the cell surface.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17513868      PMCID: PMC1978545          DOI: 10.1074/jbc.M701737200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.

Authors:  G Velasco; S Cal; A Merlos-Suárez; A A Ferrando; S Alvarez; A Nakano; J Arribas; C López-Otín
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

2.  Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1.

Authors:  M W Olson; M M Bernardo; M Pietila; D C Gervasi; M Toth; L P Kotra; I Massova; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

3.  Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage.

Authors:  D Pei
Journal:  Cell Res       Date:  1999-12       Impact factor: 25.617

4.  Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2.

Authors:  W R English; X S Puente; J M Freije; V Knauper; A Amour; A Merryweather; C Lopez-Otin; G Murphy
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

5.  Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25).

Authors:  W R English; G Velasco; J O Stracke; V Knäuper; G Murphy
Journal:  FEBS Lett       Date:  2001-02-23       Impact factor: 4.124

6.  Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion.

Authors:  Y Itoh; A Takamura; N Ito; Y Maru; H Sato; N Suenaga; T Aoki; M Seiki
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

7.  Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells.

Authors:  D V Rozanov; E I Deryugina; B I Ratnikov; E Z Monosov; G N Marchenko; J P Quigley; A Y Strongin
Journal:  J Biol Chem       Date:  2001-05-02       Impact factor: 5.157

8.  Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP.

Authors:  S Kojima; Y Itoh; S Matsumoto; Y Masuho; M Seiki
Journal:  FEBS Lett       Date:  2000-09-01       Impact factor: 4.124

9.  Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation.

Authors:  S Hernandez-Barrantes; M Toth; M M Bernardo; M Yurkova; D C Gervasi; Y Raz; Q A Sang; R Fridman
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

10.  Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils.

Authors:  T Kang; J Yi; A Guo; X Wang; C M Overall; W Jiang; R Elde; N Borregaard; D Pei
Journal:  J Biol Chem       Date:  2001-03-29       Impact factor: 5.157

View more
  27 in total

1.  Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.

Authors:  Elisa Nuti; Francesca Casalini; Salvatore Santamaria; Pamela Gabelloni; Sara Bendinelli; Eleonora Da Pozzo; Barbara Costa; Luciana Marinelli; Valeria La Pietra; Ettore Novellino; M Margarida Bernardo; Rafael Fridman; Federico Da Settimo; Claudia Martini; Armando Rossello
Journal:  Eur J Med Chem       Date:  2011-04-02       Impact factor: 6.514

2.  MT6-MMP is present in lipid rafts and faces inward in living human PMNs but translocates to the cell surface during neutrophil apoptosis.

Authors:  Carl F Fortin; Anjum Sohail; Qing Sun; Patrick P McDonald; Rafael Fridman; Tamàs Fülöp
Journal:  Int Immunol       Date:  2010-05-25       Impact factor: 4.823

Review 3.  Glycan changes: cancer metastasis and anti-cancer vaccines.

Authors:  Min Li; Lujun Song; Xinyu Qin
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

4.  Characterization of the dimerization interface of membrane type 4 (MT4)-matrix metalloproteinase.

Authors:  Anjum Sohail; Marta Marco; Huiren Zhao; Qicun Shi; Scott Merriman; Shahriar Mobashery; Rafael Fridman
Journal:  J Biol Chem       Date:  2011-08-02       Impact factor: 5.157

5.  Matrix metalloproteinases as reagents for cell isolation.

Authors:  Anna M Knapinska; Sabrina Amar; Zhong He; Sandro Matosevic; Claudia Zylberberg; Gregg B Fields
Journal:  Enzyme Microb Technol       Date:  2016-07-20       Impact factor: 3.493

Review 6.  Matrix Metalloproteinases (MMPs) in Liver Diseases.

Authors:  Adnan Naim; Qiuwei Pan; Mirza S Baig
Journal:  J Clin Exp Hepatol       Date:  2017-10-03

Review 7.  MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer.

Authors:  Anjum Sohail; Qing Sun; Huiren Zhao; M Margarida Bernardo; Jin-Ah Cho; Rafael Fridman
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

8.  Matrix metalloproteinase-25 has a functional role in mouse secondary palate development and is a downstream target of TGF-β3.

Authors:  Graham D Brown; Adil J Nazarali
Journal:  BMC Dev Biol       Date:  2010-09-01       Impact factor: 1.978

9.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

10.  Effect of PLCε gene silencing on inhibiting the cancerous transformation of ulcerative colitis.

Authors:  Kun Yang; Jing Yan; Lan Peng; Yu-Pei Zou; Fu-Qian He; Hua-Tian Gan; Xiao-Li Huang
Journal:  Exp Ther Med       Date:  2016-04-15       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.